EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.

Date publication

décembre 2016

Journal

International journal of molecular sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline

Tous les auteurs :
Tomasini P, Serdjebi C, Khobta N, Metellus P, Ouafik L, Nanni I, Greillier L, Loundou A, Fina F, Mascaux C, Barlesi F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27999344

Résumé

Lung cancer is the leading cause of brain metastases (BM). The identification of driver oncogenes and matched targeted therapies has improved outcome in non-small cell lung cancer (NSCLC) patients; however, a better understanding of BM molecular biology is needed to further drive the process in this field.

Mots clés

EGFR, KRAS, brain metastasis, incidence, lung neoplasm, recurrence, survival

Référence

Int J Mol Sci. 2016 Dec 18;17(12):